Lori J. Wirth, MD, of Massachusetts General Hospital Cancer Center, discusses the common molecular alterations across thyroid cancer subtypes; targeted treatments for BRAF V600E–mutant, NTRK–fusion positive, and RET–altered disease; and optimal therapies for patients with multiple types of thyroid cancer.
Thomas K. Varghese, Jr, MD, of Huntsman Cancer Institute at the University of Utah, summarizes a panel discussion on how the COVID-19 pandemic has interrupted cancer screenings, when telemedicine works and when it doesn’t, opening alternative care sites in the community, and the emotional and mental toll the coronavirus has taken on health-care providers.
Melinda L. Telli, MD, of Stanford Cancer Institute, discusses highlights of the new NCCN Clinical Practice Guidelines in Oncology®, including nonanthracycline, taxane-based regimens as preferred treatments for patients with HER2-positive breast cancer; newly approved combination therapies such as tucatinib plus capecitabine plus trastuzumab, margetuximab plus chemotherapy, and neratinib plus capecitabine; and recommendations for third line and beyond.
Susan M. Swetter, MD, of Stanford Cancer Institute, discusses molecular prognostic tests for cutaneous melanoma, which may improve staging accuracy, reduce unnecessary sentinel lymph node biopsies, and inform decisions on surveillance imaging and/or adjuvant therapy.
April K. Salama, MD, of Duke Cancer Institute, discusses the shift in recent years, as more effective therapies have become available, toward integrating systemic upfront treatment of patients with brain metastases from cutaneous melanoma; pivotal studies that have provided key data; and the need for a multidisciplinary approach incorporating medical, surgical, and radiation oncology.
Sandy Srinivas, MD, of Stanford Cancer Institute, discusses the increasing number of ways to deliver life-prolonging therapy to patients with advanced prostate cancer, including more accurate imaging techniques; PET tracers to help better detect, diagnose, and treat disease; PARP inhibitors for BRCA and other mutations; and new sequencing of drugs.
